Syros Pharmaceuticals Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Syros Pharmaceuticals stock.
View analyst ratings for Syros Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Syros Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Syros Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Syros Pharmaceuticals.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) announced its quarterly earnings data on Thursday, August, 5th. The company reported ($0.36) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.36). The firm had revenue of $5.16 million for the quarter, compared to the consensus estimate of $4.58 million. Syros Pharmaceuticals had a negative trailing twelve-month return on equity of 82.58% and a negative net margin of 442.40%.
View Syros Pharmaceuticals' earnings history.

Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SYRS stock has decreased by 3.7% and is now trading at $4.96.
View which stocks have been most impacted by COVID-19.

6 brokerages have issued 12-month price objectives for Syros Pharmaceuticals' stock. Their forecasts range from $13.00 to $20.00. On average, they expect Syros Pharmaceuticals' stock price to reach $16.20 in the next twelve months. This suggests a possible upside of 226.6% from the stock's current price.
View analysts' price targets for Syros Pharmaceuticals or view top-rated stocks among Wall Street analysts.

3 employees have rated Syros Pharmaceuticals CEO Nancy Simonian on Glassdoor.com. Nancy Simonian has an approval rating of 100% among Syros Pharmaceuticals' employees. This puts Nancy Simonian in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Syros Pharmaceuticals include PMV Pharmaceuticals (PMVP), ImmunoGen (IMGN), ChemoCentryx (CCXI), Enanta Pharmaceuticals (ENTA), Connect Biopharma (CNTB), Northwest Biotherapeutics (NWBO), Precigen (PGEN), MannKind (MNKD), Innoviva (INVA), Axsome Therapeutics (AXSM), Arcutis Biotherapeutics (ARQT), Bicycle Therapeutics (BCYC), RAPT Therapeutics (RAPT), GH Research (GHRS) and Repare Therapeutics (RPTX).
View all of SYRS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), ImmunoGen (IMGN), VBI Vaccines (VBIV), Amarin (AMRN), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Pfizer (PFE).

(SYRS) raised $60 million in an initial public offering (IPO) on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS."

Syros Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (14.61%), BlackRock Inc. (7.21%), Vanguard Group Inc. (4.48%), Omega Fund Management LLC (3.67%), Altium Capital Management LP (1.74%) and State Street Corp (1.61%). Company insiders that own Syros Pharmaceuticals stock include Eric R Olson, Jeremy P Springhorn, Mark J Alles, Richard A Young and Srinivas Akkaraju.
View institutional ownership trends for Syros Pharmaceuticals.

SYRS stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Redmile Group LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, PDT Partners LLC, Russell Investments Group Ltd., State of Wisconsin Investment Board, and Deutsche Bank AG.
View insider buying and selling activity for Syros Pharmaceuticals or view top insider-selling stocks.

SYRS stock was bought by a variety of institutional investors in the last quarter, including Altium Capital Management LP, Omega Fund Management LLC, Millennium Management LLC, Marshall Wace LLP, Marshall Wace LLP, BlackRock Inc., Cubist Systematic Strategies LLC, and State Street Corp. Company insiders that have bought Syros Pharmaceuticals stock in the last two years include Jeremy P Springhorn, and Mark J Alles.
View insider buying and selling activity for Syros Pharmaceuticals or or view top insider-buying stocks.

Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SYRS stock can currently be purchased for approximately $4.96.

Syros Pharmaceuticals has a market capitalization of $307.18 million and generates $15.09 million in revenue each year. The company earns $-84,040,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

Syros Pharmaceuticals employs 103 workers across the globe.

The official website for Syros Pharmaceuticals is www.syros.com.

Syros Pharmaceuticals is headquartered at 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139.

Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 744-1340 or via email at [email protected].